Natco extends scope of agreement with Akorn Inc

Hyderabad, Nov 3 (UNI) Natco Pharma Limited today announced addition of two injectable drug products to its existing API Supply and Margin Sharing Agreement with Akorn Inc., USA.

With this agreement, the total number of products covered under the agreement went up to four, a company release said here.

The two ANDA drug products were indicated for prevention of nausea and vomiting associated with cancer chemotherapy and had a combined current market size of approximately USD 360 million.

Under the API Supply and Margin Sharing Agreement signed in April 2006, NATCO would be responsible for supply of active pharmaceutical ingredients for both drug products, while Akorn would manufacture, regulatory submissions, marketing and distribution in hospitals, clinics and home healthcare markets in the US and Canada.

UNI DB VR AA 1737